OncoMatch/Clinical Trials/NCT05468242
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Is NCT05468242 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant chemo-immunotherapy and Bevacizumab for stage iii non-small cell lung cancer.
Treatment: Neoadjuvant chemo-immunotherapy · Bevacizumab · Tislelizumab — The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: chemotherapy
Without prior chemotherapy
Cannot have received: radiotherapy
Without prior radiotherapy
Cannot have received: surgery
Without prior surgery
Cannot have received: targeted therapy
Without prior targeted therapy
Cannot have received: immunotherapy
Without prior immunotherapy
Cannot have received: anti-PD-1 therapy
Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody
Lab requirements
Blood counts
Absolute neutrophil count >1.5 x 10^9/L (1500 per mm3); Platelets >100 x 10^9/L (100,000 per mm3); Haemoglobin≥9.0 g/dL (5.59 mmol/L)
Kidney function
Serum creatinine clearance(CL) >50 mL/min by the Cockcroft-Gault formula
Liver function
Serum bilirubin ≤1.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN
Absolute neutrophil count >1.5 x 10^9/L (1500 per mm3); Platelets >100 x 10^9/L (100,000 per mm3); Haemoglobin≥9.0 g/dL (5.59 mmol/L); Serum creatinine clearance(CL) >50 mL/min by the Cockcroft-Gault formula; Serum bilirubin ≤1.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05468242 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages